Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for genetic diseases, inflammatory disease, and neurologic disorders. The company's clinical-stage product candidates include AVP-786, which is in Phase 2 and Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including Alzheimer's agitation, depressive disorders, and residual schizophrenia; and CTP-656, which is in Phase I clinical trial to treat cystic fibrosis. It also has completed the Phase 1 clinical trial of CTP-730 for the treatment of inflammation or cancer; and JZP-386 for the treatment of excessive daytime sleepiness and cataplexy. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
